Here we demonstrate formulation development, optimization, and evaluation of bioactivity of OCT-targeted Lcn2 siRNA encapsulated PEGylated cationic liposomes (OCT-Lcn2-Lipo) for drug delivery to breast cancer cells like MCF-7 and MDA-MB-231. This evidence concerns the gene LCN2 and breast cancer.